Extraocular muscle transplantation.
1. The transplantation of extraocular homografts in dogs and humans has been described. 2. The extraocular muscle tissue transplanted remains viable, but loses its characteristics of muscle tissue during the period of the normal healing process following extraocular muscle surgery. 3. Autogenous homograft of extraocular muscle has an advantage over artificial synthetic material with the absence of extrusion and less reaction. 4. This is a clinically usable procedure today, especially in the amblyopic ehe with high deviation to accomplish an additional lengthening of one extraocular muscle, particularly if extraocular muscle surgery has previously been performed.
D000293:Adolescent; D000818:Animals; D002015:Bucrylate / Q000009:adverse effects; D002209:Caprolactam / Q000009:adverse effects; D002675:Child, Preschool; D004285:Dogs; D005205:Fascia / Q000637:transplantation; D000071938:Fasciotomy; D005260:Female; D006087:Graft vs Host Reaction; D006789:Host vs Graft Reaction; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D008297:Male; D008722:Methods; D009801:Oculomotor Muscles / Q000502:physiology / Q000601:surgery / Q000637:transplantation*; D011108:Polymers / Q000009:adverse effects; D011183:Postoperative Complications; D013285:Strabismus / Q000601:surgery*; D013718:Tensile Strength; D014182:Transplantation, Autologous
D011108:Polymers; D002015:Bucrylate; D002209:Caprolactam